Trial Condition(s):

Prostatic Neoplasms, Castration-Resistant

Healthcare costs of mCRPC in university hospitals in Japan

Bayer Identifier:

18530

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The study was a local, retrospective, observational, single-cohort study based on secondary data and was conducted to determine the healthcare costs in metastatic castration resistant prostate cancer (mCRPC) in national university hospitals in Japan.

Inclusion Criteria
- Patients who have been coded as having “Malignant neoplasm of prostate" (ICD-10, C61) at least once
  - Of the above patients those with at least one confirmed bone metastases site coded as “Secondary malignant neoplasm of other and unspecified sites" (ICD-10, C79)
 - Of the above patients those who have been coded as having “Bone metastatic prostate cancer" (ICD-10, C795) and received Androgen Deprivation Therapy (ADT) at least once since diagnosis or CRPC treatment (Abiraterone acetate, Enzalutamide, Docetaxel, Cabazitaxel) at least once since diagnosis.
  - Patients who have been coded as having “Castration-resistant prostate cancer” (ICD-10, C61 and Japanese 8848040)
Exclusion Criteria
- Patients who have been observed less than 6 months

Trial Summary

Enrollment Goal
4001
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Unspecified
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

Trial Design